Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib

Immuneering Corp

In 55-patient ITT population, mOS 17.3 months (cutoff Apr 24, 2026) vs 8.5 months standard of care.
mPFS 8.3 months; ORR 36% (18/50), DCR 82% (41/50) in response-evaluable patients.
84% of evaluable patients maintained or gained weight; Grade ≥3 TEAEs: Anemia 16%, Neutropenia 18%.
Expects first patient dosed in pivotal Phase 3 (MAPKeeper 301) mid-2026; topline data mid-2028.
Plans Phase 1b/2 trial of atebimetinib+Libtayo in NSCLC starting H2 2026; data late 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.